Lana Rifkin, MD
Uveitis and Ocular Inflammatory Disease · Boston, MANPI 1053553867
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 52.9% of the total. Reporting peaked in 2022 at $26,403 and has fallen 75.0% since, to $6,589 in 2025.
Across 100 payments — averaging $767.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$41K
- AbbVie$14K
- Eyepoint US, Inc.$11K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$8K
- Kala Pharmaceuticals, Inc.$3K
- Alcon$208
- plus $908 from 14 others
Across 13 payments — averaging $2232.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$20K
- Eyepoint US, Inc.$9K
What the payments were for
- Consulting fees$45,21059%
- Speaking & faculty fees$27,36136%
- Travel & lodging$2,2593%
- Food & beverage$1,9102%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 43 | $40,590 |
| AbbVie(2 entities) | 15 | $13,552 |
| Eyepoint US, Inc. | 8 | $11,388 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $7,523 |
| Kala Pharmaceuticals, Inc. | 2 | $2,570 |
| Alcon | 2 | $208 |
| Dompe US, Inc. | 2 | $168 |
| Apellis Pharmaceuticals, Inc. | 1 | $118 |
| Genentech USA, Inc. | 1 | $117 |
| ANI Pharmaceuticals, Inc. | 5 | $101 |
| Oyster Point Pharma, Inc. | 1 | $89 |
| Tarsus Pharmaceuticals, Inc. | 3 | $78 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Sun Pharmaceutical Industries Inc. | 1 | $40 |
| Mallinckrodt Enterprises LLC | 2 | $38 |
| Alimera Sciences, Inc. | 2 | $31 |
| Amgen | 1 | $23 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
| Novartis | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few uveitis and ocular inflammatory disease providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 77 | $577,755 |
| Difluprednate | 318 | $32,416 |
| Prednisolone Acetate | 460 | $22,560 |
| Mycophenolate Mofetil | 110 | $18,345 |
| ValacyclovirValacyclovir Hcl | 260 | $15,200 |
| Restasis MultidoseCyclosporine | 12 | $9,458 |
| ZirganGanciclovir | 13 | $6,015 |
| LotemaxLoteprednol Etabonate | 15 | $4,434 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 19 | $4,300 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 77 | $1,563 |
| Famciclovir | 15 | $1,343 |
| Fluorometholone | 19 | $1,228 |
| MethotrexateMethotrexate Sodium | 60 | $1,087 |
| Timolol Maleate | 115 | $917 |
| Brimonidine Tartrate | 71 | $862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis Multidose | $13,552 | $9,45812 claims |
| Bausch & Lomb Americas Inc.Zirgan | $40,590 | $6,01513 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax | $7,523 | $4,43415 claims |
| AlconSimbrinza | $208 | $4,30019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few uveitis and ocular inflammatory disease providers in Massachusettson file to place this against a meaningful peer group, so we don't.
Other uveitis and ocular inflammatory disease in Boston
- Caroline BaumalBoston$824K
- Elias ReichelBoston$674K
- Nadia WaheedBoston$346K
- Jay DukerBoston$22K
- Andrew TyeBoston$918
- Sarkis SoukiasianBurlington$196
- Arnold KrollMilford$118
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.